Relationship between the clinical manifestations of sickle cell disease and the expression of adhesion molecules on white blood cells

European Journal of Haematology

Volumn 69, Issue 3, 2002, Pages 135-144

  Okpala, Iheanyi ^a   Daniel, Yvonne ^a   Haynes, Roberta ^a   Odoemene, Damian ^a   Goldman, John ^b  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Adhesion molecules; Leukocytes; Sickle cell

Indexed keywords

CELL ADHESION MOLECULE; HEMOGLOBIN F; HYDROXYUREA; INTEGRIN; L SELECTIN;

ADOLESCENT; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BLOOD VESSEL OCCLUSION; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG MECHANISM; FEMALE; GENOTYPE; HEMOGLOBIN DETERMINATION; HUMAN; KIDNEY DISEASE; LEUKOCYTE ADHERENCE; LEUKOCYTE COUNT; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SICKLE CELL ANEMIA; SICKLE CELL CRISIS; STEADY STATE; VASCULAR ENDOTHELIUM;

ADULT; ANEMIA, SICKLE CELL; BIOLOGICAL MARKERS; CELL ADHESION MOLECULES; FEMALE; HOMOZYGOTE; HUMANS; LEUKOCYTES; MALE; PREGNANCY; PROGNOSIS;

EID: 0036757797     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0609.2002.02775.x     Document Type: Article

References (55)

1. Steinberg MH, Hebble RP. Clinical diversity of sickle cell anaemia: Genetic and cellular modulation of disease severity. Am J Hematol 1983;14: 405-416.
2. Thomas PW, Higgs DR, Serjeant GR. Benign clinical course in homozygous sickle cell disease: A search for predictors. J Clin Epidemiol 1997;50: 121-126.
3. Steinberg MH. Pathophysiology of sickle cell disease. Bailliere's Clin Haematol 1998;11: 163-183.
4. Attah EB. The pathophysiology of sickle cell disease. In: Fleming, A F, ed. Sickle Cell Disease: A Handbook for the General Clinician. Edinburgh: Churchill Livingstone 1982: 43-56.
5. 1 and glycoprotein IV (CD36) are expressed on circulating reticulocytes in sickle cell anemia. Blood 1993;82: 3548-3555.
6. 1 integrin expression in sickle reticulocytes: Vascular cell adhesion molecule-1 dependent binding to endothelium. Blood 1993;82: 1891-1899.
7. Udani M, Zen Q, Cottman M, et al. Basal cell adhesion molecule/Lutheran protein. The receptor critical for sickle cell adhesion to laminin. J Clin Invest 1997;99: 2561-2564.
8. Setty YBN, Kulkami S, Stuart MJ. Role of erythrocyte phosphatidylserine in sickle red cell-endothelial adhesion. Blood 2002;99: 1564-1571.
9. Manodori AB, Barabino GA, Lubin BH, Kuypers FA. Adherence of phosphatidyl-exposing erythrocytes to endothelial matrix thrombospondin. Blood 2000;95: 1293-1300.
10. Anyaegbu CC, Okpala IE, Aken'Ova AY, Salimonu LS. Peripheral blood neutrophil count and candidacidal activity correlate with the clinical severity of sickle cell anaemia. Eur J Haematol 1998;60: 267-268.
11. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease - Life expectancy and risk factors for early death. N Engl J Med 1994;330: 1639-1643.
12. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crisis in sickle cell anemia N Engl J Medical 1995;322: 1314-1322.
13. Charache S. The mechanism of action of hydroxyurea in the management of sickle cell anaemia in adults. Semin Hematol 1997;34: 15-21.
14. Abboud MR, Laver J, Blau CA. Elevation of neutrophil count after G-CSF therapy leads to vaso-occlusive crisis and acute chest syndrome in a patient with sickle cell anaemia. Blood 1996;88: 15b.
15. Steinberg MH, Rodgers GP. Pathophysiology of sickle cell disease: Role of genetic and cellular modifiers. Semin Hematol 2001;38: 299-306.
16. 2 integrins. J Cell Biol 1991;115: 223-234.
17. 2 integrins in vivo. Proc Natl Acad Sci USA 1991;88: 7538-7542.
18. Tan P, Luscinkas FW, Homer-Vanniasinkams S. Cellular and molecular mechanisms of inflammation and thrombosis (review). Eur J Vasc Endovasc Surg 1999;17: 373-389.
19. Guyer DA, Moore KL, Lynam EB, et al. P-selectin glycoprotein ligand (PSGL-1) is a ligand for L-selectin in neutrophil aggregation. Blood 1996;88: 2415-2421.
20. Walcheck B, Moore KL, McEver RP, Kishimoto TK. Neutrophil-neutrophil interactions under hydrodynamic shear stress involve L-selectin and PSGL-1. A mechanism that amplifies initial leukocyte accumulation of P-selectin in vitro. J Clin Invest 1996;98: 1081-1087.
21. Patel KD, Moore KL, Nollert MU, McEver RP. Neutrophils use both shared and distinct mechanisms to adhere to selectins under static and flow conditions. J Clin Invest 1996;96: 1887-1896.
22. Chan JY-H, Watt SM. Adhesion receptors on haemopoietic progenitor cells. Br J Haematol 2001;112: 541-557.
23. Carlos TM, Harlan JM. Leukocyte-endothelial adhesion molecules. Blood 1994;84: 2068-2101.
24. Watt SM, Gschmeissner SE, Bates PA. PECAM-1. Its expression and function as an adhesion molecule on haemopoietic and endothelial cells. Leukaemia Lymphoma 1995;17: 229-244.
25. + cells across specialized and nonspecialized endothelium requires prior activation by growth factors and is mediated by PECAM-1 (CD31). Blood 1998;91: 1196-1205.
26. Daviet L, McGregor JL. Vascular biology of CD36: Roles of this new adhesion molecule family in different disease states (review). Thromb Haemost 1997;78: 65-69.
27. Britain HA, Eckman JR, Swerlick RA, et al. Thrombospondin from activated platelets promotes sickle erythrocyte adherence to human microvascular endothelium under physiologic flow: A potential for platelet activation in sickle cell vaso-occlusion. Blood 1993;81: 2137-2153.
28. Hebble RP. Adhesive interactions of sickle erythrocytes with endothelium. J Clin Invest 1997;99: 2561-2564.
29. Silverstein RL, Asch AS, Nachman RL. Glycoprotein IV mediates thrombospondin- dependent platelet-monocyte and platelet-U937 cell adhesion. J Clin Invest 1989;84: 546-552.
30. Etzioni A, Doerschik CM, Harlan JM. Of man and mouse, leukocyte and endothelial adhesion molecule deficiencies. Blood 1999;94: 3281-3288.
31. Sommers WS, Tang J, Shaw GD, Camphausen RT. Insights into the molecular basis of leukocyte tethering and rolling revealed by structures of P and E-selectin bound to SLe (X) and PSGL-1. Cell 2000;103: 467-479.
32. Gonzalez-Amaro R, Sanchez-Madrid F. Cell adhesion molecules. Selectins and integrins. Crit Rev Immunol 1999;19: 389-429.
33. Yang J, Furie BC, Furie B. The biology of P-selectin glycoprotein ligand-1: Its role as a selectin counterreceptor in leukocyte-endothelial and leukocyte-platelet interaction. Thromb Haemost 1999;81: 1-7.
34. Powars DR. βs - Gene-cluster haplotypes in sickle cell anemia. Clinical and hematologic features. Hematol Oncol Clin North Am 1991;5: 475-493.
35. Ferster A, Vermylen C, Cornu G, et al. Hydroxyurea for treatment of severe sickle cell anemia: A pediatric clinical trial. Blood 1996;88: 1960-1964.
36. Kinney TR, Helms RW, O'Branski EE, et al. Pediatric hydroxyurea Group: Safety of hydroxyurea in children with sickle cell anemia: Results of the HUG-KIDS study, a phase I/II trial. Blood 1999;94: 1550-1554.
37. Hedo CC, Okpala IE, Aken'Ova AY, Salimonu LS. Correlates of severity in sickle cell anemia. Blood 1996;88: 17b.
38. Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: Rates and risk factors. Blood 1998;91: 288-294.
39. Powars DR. Management of cerebral vasculopathy in children with sickle cell anaemia (review). Br J Haem 2000;108: 666-678.
40. Ataga KI, Orringer EU. Renal abnormalities in sickle cell disease. Am J Hematol 2000;63: 205-211.
41. Guasch A, Cua M, Mitch WE. Early detection and the course of glomerular injury inpatients with sickle cell anemia. Kidney Int 1996;49: 786-791.
42. Falk RJ, Scheinmn J, Phillips G, Orringer E, Johnson A, Jennette JC. Prevalence and pathologic features of sickle cell nephropathy and response to inhibition of angiotensin-converting enzyme. N Engl J Med 1992;326: 910-915.
43. Okpala IE. The management of crisis in sickle cell disease (review). Eur J Haematol 1998;60: 1-6.
44. Attah Ed B, Ekere MC. Death patterns in sickle cell anemia. JAMA 1975;233: 889-890.
45. Serjeant GR. Sickle cell disease. Lancet 1997;350: 725-730.
46. Styles LA, Lubin B, Vichinsky E, et al. Decrease of very late activation antigen-4 and CD36 expression on reticulocytes in sickle cell patients treated with hydroxyurea. Blood 1997;89: 2554-2559.
47. Hillery CA, Du MC, Wang WC, Scott JP. Hydroxyurea therapy decreases in vitro adhesion of sickle erythrocytes to thrombospondin and laminin. Br J Haematol 2000; 109: 322-327.
48. 2 production of polymorphonuclear neutrophils from patients with sickle cell anemia. Blood 2002;99: 2297-2303.
49. Hedo CC, Aken'Ova YA, Okpala IE, Durojaiye AO, Salimonu LS. Acute phase reactants and the severity of homozygous sickle cell anaemia. J Intern Med 1993; 223: 467-470.
50. Anyaegbu CC, Okpala IE, Aken'Ova AY, Salimonu LS. Complement haemolytic activity, circulating immune complexes, and the morbidity of sickle cell anaemia. Acta Pathol Microbiol Scand (APMIS) 1999;107: 699-702.
51. Fearon DT, Collins LA. Increased expression of C3b receptors on polymorphonuclear. Leukocytes induced by chemotactic factors and by purification procedures. J Immunol 1983;130: 370-375.
52. Lard LR, Mul FPJ, De Haas M, Roos D, Dults AJ. Neutrophil activation in sickle cell disease. J Leukocyte Biol; 1999;66: 411-415.
53. Bain BJ. Ethnic and sex differences in the total and differential white cell count and platelet count. J Clin Pathol 1996;49: 664-666.
54. Shaper AG, Lewis P. Genetic neutropenia in people of African ancestry. Lancet 1971;2: 1021.
55. Goldman JM. Granulocytes, monocytes, and their benign disorders. In: Hoffbrand, AV, Lewis, SM, eds. Postgraduate Haematology. Oxford: Butterworth Heinemann, 1989: 294-324.